Eli Lilly and Company (NYSE:LLY) Trading 1.4% Higher – Here’s What Happened

Eli Lilly and Company (NYSE:LLY)’s stock price rose 1.4% during trading on Wednesday . The company traded as high as $922.15 and last traded at $915.7140. Approximately 2,155,156 shares traded hands during trading, a decline of 33% from the average daily volume of 3,195,379 shares. The stock had previously closed at $903.02.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Morgan Stanley reiterated an Overweight rating and a $1,313 price target, citing the growth potential of Lilly’s new employer access platform for obesity therapies — a strong sell‑side endorsement that supports upside expectations. Read More.
• Positive Sentiment: Lilly completed a pediatric pharmacokinetics study for a next‑generation diabetes drug (Phase 1 update), de‑risking a program that could expand the diabetes franchise if later‑stage results succeed. Read More.
• Positive Sentiment: Investor letters and coverage note that Lilly’s GLP‑1/obesity drugs remain the core growth driver; RiverPark and other commentators highlight continued revenue momentum that underpins earnings upside. Read More.
• Positive Sentiment: Retail/pharmacy expansion: Kroger pharmacies have begun offering Lilly’s Zepbound KwikPen with support/savings programs, widening patient access and potentially boosting volumes. Read More.
• Positive Sentiment: High‑profile endorsements: Jim Cramer continues to list Lilly among his top healthcare picks, which can attract retail inflows and reinforce positive sentiment. Read More.
• Positive Sentiment: Leadership and pipeline focus: Reporting on an external executive’s role in driving Lilly’s oncology pipeline (Loxo assets) suggests management is prioritizing high‑value R&D initiatives. Read More.
• Neutral Sentiment: Relative valuation and peer comparisons (Novo Nordisk, AbbVie) produce mixed views — analysts debate whether Lilly’s multiple already prices in GLP‑1 growth, leaving valuation as a watchpoint. Read More.
• Neutral Sentiment: Analyst comparisons (LLY vs ABBV) and ETF commentary suggest different playbooks for investors (direct exposure vs diversified healthcare), useful for portfolio positioning but not an immediate catalyst. Read More.
• Negative Sentiment: Lilly plans to phase out select insulin products across Europe by 2027, a move that could modestly disrupt revenue in that region and requires monitoring for transitional volumes/pricing impact. Read More.
• Negative Sentiment: Local scrutiny of a large Lilly development project (LVPC review) raises near‑term execution/permits risk for that specific buildout; operational risk is localized but worth watching. Read More.

Wall Street Analysts Forecast Growth

LLY has been the topic of several recent research reports. Argus raised their target price on shares of Eli Lilly and Company from $930.00 to $1,200.00 and gave the stock a “buy” rating in a report on Monday, February 9th. HSBC cut Eli Lilly and Company from a “hold” rating to a “reduce” rating and cut their price target for the company from $1,070.00 to $850.00 in a research note on Tuesday, March 17th. Zacks Research lowered Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 30th. UBS Group reaffirmed a “buy” rating on shares of Eli Lilly and Company in a report on Wednesday, March 18th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a $1,285.00 target price on shares of Eli Lilly and Company in a research report on Friday, March 6th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and an average target price of $1,221.44.

Eli Lilly and Company Stock Performance

The company has a debt-to-equity ratio of 1.54, a quick ratio of 1.19 and a current ratio of 1.58. The company has a market cap of $865.18 billion, a P/E ratio of 39.90, a P/E/G ratio of 1.06 and a beta of 0.40. The stock’s fifty day moving average price is $1,016.28 and its two-hundred day moving average price is $961.72.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $7.48 by $0.06. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The business had revenue of $19.29 billion for the quarter, compared to analysts’ expectations of $17.85 billion. During the same period last year, the firm posted $5.32 earnings per share. The firm’s quarterly revenue was up 42.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, equities analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Hedge Funds Weigh In On Eli Lilly and Company

Institutional investors have recently modified their holdings of the business. Brighton Jones LLC grew its position in Eli Lilly and Company by 22.0% in the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock valued at $7,409,000 after acquiring an additional 1,730 shares during the last quarter. Revolve Wealth Partners LLC raised its stake in Eli Lilly and Company by 2.8% during the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock worth $1,136,000 after acquiring an additional 40 shares in the last quarter. Schnieders Capital Management LLC. lifted its holdings in shares of Eli Lilly and Company by 16.7% in the second quarter. Schnieders Capital Management LLC. now owns 7,993 shares of the company’s stock worth $6,231,000 after acquiring an additional 1,141 shares during the last quarter. Proactive Wealth Strategies LLC lifted its holdings in shares of Eli Lilly and Company by 5.6% in the second quarter. Proactive Wealth Strategies LLC now owns 1,398 shares of the company’s stock worth $1,090,000 after acquiring an additional 74 shares during the last quarter. Finally, Jefferies Financial Group Inc. boosted its stake in shares of Eli Lilly and Company by 35.9% in the 2nd quarter. Jefferies Financial Group Inc. now owns 8,128 shares of the company’s stock valued at $6,336,000 after purchasing an additional 2,146 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.